These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 39183639)

  • 1. Renoprotective effects of empagliflozin in high-fat diet-induced obesity-related glomerulopathy by regulation of gut-kidney axis.
    Lei L; Zhu T; Cui TJ; Liu Y; Hocher JG; Chen X; Zhang XM; Cai KW; Deng ZY; Wang XH; Tang C; Lin L; Reichetzeder C; Zheng ZH; Hocher B; Lu YP
    Am J Physiol Cell Physiol; 2024 Oct; 327(4):C994-C1011. PubMed ID: 39183639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empagliflozin ameliorates type 2 diabetes mellitus-related diabetic nephropathy via altering the gut microbiota.
    Deng L; Yang Y; Xu G
    Biochim Biophys Acta Mol Cell Biol Lipids; 2022 Dec; 1867(12):159234. PubMed ID: 36185030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nascent shifts in renal cellular metabolism, structure, and function due to chronic empagliflozin in prediabetic mice.
    Shepard BD; Chau J; Kurtz R; Rosenberg AZ; Sarder P; Border SP; Ginley B; Rodriguez O; Albanese C; Knoer G; Greene A; De Souza AMA; Ranjit S; Levi M; Ecelbarger CM
    Am J Physiol Cell Physiol; 2024 Apr; 326(4):C1272-C1290. PubMed ID: 38602847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empagliflozin attenuates liver fibrosis in high-fat diet/streptozotocin-induced mice by modulating gut microbiota.
    Huang C; Qian J; Liu Y; Zhang L; Yang Y
    Clin Exp Pharmacol Physiol; 2024 Mar; 51(3):e13842. PubMed ID: 38302074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Sichuan Dark Tea-Based Medicated Dietary Formula Improves Obesity-Induced Renal Lipid Metabolism Disorder in Mice by Remodeling Gut Microbiota and Short-Chain Fatty Acid Metabolism].
    Li H; Zhang L; Huang R; Ren Q; Guo F; Shi M; Yang L; Yu Y; Ma L; Fu P
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Nov; 54(6):1112-1120. PubMed ID: 38162058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empagliflozin alleviates neuroinflammation by inhibiting astrocyte activation in the brain and regulating gut microbiota of high-fat diet mice.
    Huang Q; Liu L; Tan X; Wang S; Wang S; Luo J; Chen J; Yang N; Jiang J; Liu Y; Hong X; Guo S; Shen Y; Gao F; Feng H; Zhang J; Shen Q; Li C; Ji L
    J Affect Disord; 2024 Sep; 360():229-241. PubMed ID: 38823591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empagliflozin alleviates obesity-related cardiac dysfunction via the activation of SIRT3-mediated autophagosome formation.
    Luo Y; Ye T; Tian H; Song H; Kan C; Han F; Hou N; Sun X; Zhang J
    Lipids Health Dis; 2024 Sep; 23(1):308. PubMed ID: 39334359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK).
    Domon A; Katayama K; Sato T; Tochigi Y; Tazaki H; Suzuki H
    PLoS One; 2021; 16(5):e0251135. PubMed ID: 33945582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Green Tea Polyphenols Modulate Colonic Microbiota Diversity and Lipid Metabolism in High-Fat Diet Treated HFA Mice.
    Wang L; Zeng B; Liu Z; Liao Z; Zhong Q; Gu L; Wei H; Fang X
    J Food Sci; 2018 Mar; 83(3):864-873. PubMed ID: 29427445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatoprotective and cardioprotective effects of empagliflozin in spontaneously hypertensive rats fed a high-fat diet.
    Hojná S; Malínská H; Hüttl M; Vaňourková Z; Marková I; Miklánková D; Hrdlička J; Papoušek F; Neckář J; Kujal P; Behuliak M; Rauchová H; Kadlecová M; Sedmera D; Neffeová K; Zábrodská E; Olejníčková V; Zicha J; Vaněčková I
    Biomed Pharmacother; 2024 May; 174():116520. PubMed ID: 38581924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lingguizhugan decoction attenuates diet-induced obesity and hepatosteatosis
    Liu MT; Huang YJ; Zhang TY; Tan LB; Lu XF; Qin J
    World J Gastroenterol; 2019 Jul; 25(27):3590-3606. PubMed ID: 31367159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fubrick tea attenuates high-fat diet induced fat deposition and metabolic disorder by regulating gut microbiota and caffeine metabolism.
    Jing N; Liu X; Jin M; Yang X; Hu X; Li C; Zhao K
    Food Funct; 2020 Aug; 11(8):6971-6986. PubMed ID: 32697259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
    Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut microbiota-mediated xanthine metabolism is associated with resistance to high-fat diet-induced obesity.
    Wei B; Wang S; Wang Y; Ke S; Jin W; Chen J; Zhang H; Sun J; Henning SM; Wang J; Wang H
    J Nutr Biochem; 2021 Feb; 88():108533. PubMed ID: 33250443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Puerarin Modulates Hepatic Farnesoid X Receptor and Gut Microbiota in High-Fat Diet-Induced Obese Mice.
    Yang CW; Liu HM; Chang ZY; Liu GH; Chang HH; Huang PY; Lee TY
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1-Adiponectin Axis.
    Ye T; Zhang J; Wu D; Shi J; Kuang Z; Ma Y; Xu Q; Chen B; Kan C; Sun X; Han F
    Front Endocrinol (Lausanne); 2022; 13():907984. PubMed ID: 35784553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT2 inhibition leads to a restoration of hepatic and circulating metabolites involved in the folate cycle and pyrimidine biosynthesis.
    Mendez Espinoza I; Choos END; Ecelbarger CM; Shepard BD
    Am J Physiol Gastrointest Liver Physiol; 2024 Aug; 327(2):G235-G253. PubMed ID: 38915277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empagliflozin Protects against Diet-Induced NLRP-3 Inflammasome Activation and Lipid Accumulation.
    Benetti E; Mastrocola R; Vitarelli G; Cutrin JC; Nigro D; Chiazza F; Mayoux E; Collino M; Fantozzi R
    J Pharmacol Exp Ther; 2016 Oct; 359(1):45-53. PubMed ID: 27440421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal outcomes with sodium glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, in obese insulin-resistant model.
    Jaikumkao K; Pongchaidecha A; Chueakula N; Thongnak L; Wanchai K; Chatsudthipong V; Chattipakorn N; Lungkaphin A
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt A):2021-2033. PubMed ID: 29572114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.